Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous

We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kouki, Ines, Montagner, Clémence, Mauhin, Wladimir, London, Jonathan, Lazard, Thierry, Grimbert, Sylvie, Zeller, Valérie, Lidove, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Copernicus GmbH 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131959/
https://www.ncbi.nlm.nih.gov/pubmed/34084701
http://dx.doi.org/10.5194/jbji-6-131-2021
_version_ 1783694819217899520
author Kouki, Ines
Montagner, Clémence
Mauhin, Wladimir
London, Jonathan
Lazard, Thierry
Grimbert, Sylvie
Zeller, Valérie
Lidove, Olivier
author_facet Kouki, Ines
Montagner, Clémence
Mauhin, Wladimir
London, Jonathan
Lazard, Thierry
Grimbert, Sylvie
Zeller, Valérie
Lidove, Olivier
author_sort Kouki, Ines
collection PubMed
description We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifampicin use. This deficiency should be assessed before prescribing cefazolin–rifampicin and prothrombin time monitored.
format Online
Article
Text
id pubmed-8131959
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Copernicus GmbH
record_format MEDLINE/PubMed
spelling pubmed-81319592021-06-02 Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous Kouki, Ines Montagner, Clémence Mauhin, Wladimir London, Jonathan Lazard, Thierry Grimbert, Sylvie Zeller, Valérie Lidove, Olivier J Bone Jt Infect Case Report We describe a 79-year-old man with spondylodiscitis and unknown pathogen, treated with cefazolin and rifampicin. He developed a massive digestive hemorrhage. Prothrombin time was prolonged with severe vitamin-K-dependent clotting-factor deficiency. Severe bleeding can occur during cefazolin and rifampicin use. This deficiency should be assessed before prescribing cefazolin–rifampicin and prothrombin time monitored. Copernicus GmbH 2021-04-01 /pmc/articles/PMC8131959/ /pubmed/34084701 http://dx.doi.org/10.5194/jbji-6-131-2021 Text en Copyright: © 2021 Ines Kouki et al. https://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
spellingShingle Case Report
Kouki, Ines
Montagner, Clémence
Mauhin, Wladimir
London, Jonathan
Lazard, Thierry
Grimbert, Sylvie
Zeller, Valérie
Lidove, Olivier
Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_full Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_fullStr Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_full_unstemmed Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_short Coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
title_sort coagulation disorders during treatment with cefazolin and rifampicin: rare but dangerous
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131959/
https://www.ncbi.nlm.nih.gov/pubmed/34084701
http://dx.doi.org/10.5194/jbji-6-131-2021
work_keys_str_mv AT koukiines coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT montagnerclemence coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT mauhinwladimir coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT londonjonathan coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT lazardthierry coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT grimbertsylvie coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT zellervalerie coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous
AT lidoveolivier coagulationdisordersduringtreatmentwithcefazolinandrifampicinrarebutdangerous

Ejemplares similares